Domainex

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates already in clinic.

Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.

 Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 for both oncology and inflammation and a number of epigenetics related lysine methyltransferases, including G9a.

Company type
Dr Eddy Littler
Chief Executive Officer 

Illingworth Research Ltd

Founded as Clinical Development & Support Services Ltd (CDSS)  in 1998, Illingworth Research is a Clinical Research Organisation (CRO) providing a wide range of clinical development services to the pharmaceutical, healthcare, biotechnology and medical device industries. We are experts in the management of Phase I to IV clinical trials across many different therapeutic areas. | From our base in Cheshire UK, where we are co-located with our sister company ResearchNurses.co, we offer the ultimate clinical research outsourcing partnership for sponsors across the globe. | We have worked with all types of clients, from start-up biotechnology companies to large international pharmaceutical companies, providing strong sponsor/CRO partnerships to deliver a competitive advantage.

Company type
Mr Kieran Casey

Polytherics

PolyTherics is a biotechnology company that applies precision chemistry to develop protein and peptide-based drugs. PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.

Donna Hackett

Synpromics

Synpromics is a life science company focused on the field of synthetic biology. The Company's proprietary technology enables the design of optimized synthetic promoters that provide more effective and efficient gene regulation.

Company type
David Lawrence
Michael Roberts